In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $61.68, with a -1.03% movement compared to the previous day. The stock's performance was behind the S&P 500's daily loss of 0.13%. Meanwhile, the Dow gained 0.33%, and the Nasdaq, a tech-heavy index, lost 0.39%. Shares of the company witnessed a loss of 0.53% over the previous month, beating the performance of the Medical sector with its loss of 2.05% and underperforming the S&P 500's gain of 2.43%. Investors will be eagerly watching for t ...

Viking Therapeutics NASDAQ: VKTX has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising clinical trial results for VK2735, an investigational weight loss drug that has demonstrated promising efficacy in oral and injectable forms. Viking Therapeutics Today VKTX Viking Therapeutics $62.32 -0.81 (-1.28%) 52-Week Range $8.28 ▼ $99.41 Price Target $108.60 Add to Watchlist The company is expected to report it ...

Company Performance - Viking Therapeutics, Inc. (VKTX) closed at $63.13, reflecting a +1.94% increase compared to the previous day, outperforming the S&P 500's daily loss of 0.19% [1] - Over the past month, the company's shares appreciated by 0.85%, while the Medical sector experienced a loss of 1.58% and the S&P 500 gained 1.95% [1] Earnings Expectations - The company is expected to report an EPS of -$0.24, which is a decrease of 4.35% from the prior year quarter [2] Analyst Forecasts - Recent revisions to analyst forecasts for Viking Therapeutics are important, as they reflect changes in short-term business dynamics, with positive revisions indicating analyst optimism about the company's profitability [3] - The consensus EPS projection has decreased by 0.99% in the past 30 days, and Viking Therapeutics currently holds a Zacks Rank of 3 (Hold) [5] Industry Context - Viking Therapeutics operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 82, placing it in the top 33% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Hardly for the first time, a pundit following the company waxed bullish on its future. Viking Therapeutics (VKTX 1.94%), a biotech stock that has rocketed to prominence thanks to one of its investigational drugs, gave investors more reason to like it on Wednesday. The company's share price rose by almost 2% following an analyst's bullish new research note; that increase stood in positive contrast to the 0.2% decline of the S&P 500 index. Weight loss drug in the spotlight The author of that note was Oppenhei ...

Core Viewpoint - Viking Therapeutics, Inc. (NASDAQ: VKTX) is likely to be acquired by a large pharmaceutical firm due to the strong efficacy of its weight-loss drug VK2735 [1] Group 1 - The drug VK2735 has shown strong efficacy, which positions the company favorably for potential acquisition [1]

Viking Therapeutics Today VKTX Viking Therapeutics $64.45 +1.51 (+2.40%) 52-Week Range $8.28 ▼ $99.41 Price Target $108.60 Add to Watchlist Viking Therapeutics Inc. NASDAQ: VKTX, a clinical-stage biotechnology company with a market cap approaching $7 billion, is turning heads in 2024. Year to date, the stock has surged an impressive 238%, and its rise over the past 12 months has been even more dramatic, with shares climbing 326%. For a mid-cap biotech, these kinds of gains significantly outpace both the bro ...

Company Performance - Viking Therapeutics, Inc. (VKTX) closed at $67.10, reflecting a +0.55% change from the previous day's closing price, outperforming the S&P 500's gain of 0.13% [1] - The company's shares increased by 17.67% over the past month, significantly surpassing the Medical sector's gain of 3.34% and the S&P 500's gain of 3.67% [1] Earnings Forecast - The upcoming earnings release is anticipated, with a forecasted EPS of -$0.24, indicating a 4.35% decline compared to the same quarter last year [2] Analyst Estimates - Recent changes to analyst estimates for Viking Therapeutics are noteworthy, as positive revisions are generally seen as a favorable indicator for the company's business outlook [3] - The Zacks Rank system, which reflects these estimate changes, provides actionable insights for investors [4] Zacks Rank and Industry Performance - Viking Therapeutics currently holds a Zacks Rank of 3 (Hold), with a 0.99% decrease in the Zacks Consensus EPS estimate over the past month [5] - The Medical - Biomedical and Genetics industry, which includes Viking Therapeutics, has a Zacks Industry Rank of 83, placing it in the top 33% of over 250 industries, indicating strong performance potential [6]

The company is looking especially good after some bad news coming from a rival. For the second day in a row, a pundit's take on Viking Therapeutics (VKTX 3.25%) helped push the biotech's share price higher. It was this rather than inherent news from the company that added more than 3% to said price, a gain that handily beat the S&P 500 index's 0.8% increase. Thumbs-up from bullish pundit The latest analyst to weigh in on Viking's prospects was Morgan Stanley's Michael Ulz, who early Thursday morning publish ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Viking Therapeutics, Inc. (VKTX) . Viking Therapeutics currently ...

The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug. Viking Therapeutics (VKTX 11.31%) stormed the stock market on Wednesday. Shares of the up-and-coming biotech rose by more than 11% not on any proprietary news from the company, but on an analyst's initiation of coverage. That performance was more than enough to top the trajectory of the bellwether S&P 500 index, which rose by slightly over 1% on the day. 32% upside potential, analyst b ...